329 related articles for article (PubMed ID: 32462078)
1. Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.
Loff S; Dietrich J; Meyer JE; Riewaldt J; Spehr J; von Bonin M; Gründer C; Swayampakula M; Franke K; Feldmann A; Bachmann M; Ehninger G; Ehninger A; Cartellieri M
Mol Ther Oncolytics; 2020 Jun; 17():408-420. PubMed ID: 32462078
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML.
Meyer JE; Loff S; Dietrich J; Spehr J; Jurado Jiménez G; von Bonin M; Ehninger G; Cartellieri M; Ehninger A
Oncoimmunology; 2021; 10(1):1945804. PubMed ID: 34290907
[TBL] [Abstract][Full Text] [Related]
3. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Peschke JC; Bergmann R; Mehnert M; Gonzalez Soto KE; Loureiro LR; Mitwasi N; Kegler A; Altmann H; Wobus M; Máthé D; Szigeti K; Feldmann A; Bornhäuser M; Bachmann M; Fasslrinner F; Arndt C
Br J Haematol; 2023 Sep; 202(6):1137-1150. PubMed ID: 37460273
[TBL] [Abstract][Full Text] [Related]
4. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
[TBL] [Abstract][Full Text] [Related]
5. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
[TBL] [Abstract][Full Text] [Related]
6. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
7. Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).
Mitwasi N; Arndt C; Loureiro LR; Kegler A; Fasslrinner F; Berndt N; Bergmann R; Hořejší V; Rössig C; Bachmann M; Feldmann A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563312
[TBL] [Abstract][Full Text] [Related]
8. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
Wermke M; Kraus S; Ehninger A; Bargou RC; Goebeler ME; Middeke JM; Kreissig C; von Bonin M; Koedam J; Pehl M; Bornhäuser M; Einsele H; Ehninger G; Cartellieri M
Blood; 2021 Jun; 137(22):3145-3148. PubMed ID: 33624009
[No Abstract] [Full Text] [Related]
9. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
11. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
13. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
14. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
15. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
[TBL] [Abstract][Full Text] [Related]
16. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Boucher JC; Shrestha B; Vishwasrao P; Leick M; Cervantes EV; Ghafoor T; Reid K; Spitler K; Yu B; Betts BC; Guevara-Patino JA; Maus MV; Davila ML
Mol Ther Oncolytics; 2023 Dec; 31():100751. PubMed ID: 38075241
[TBL] [Abstract][Full Text] [Related]
17. Retargeting of UniCAR T cells with an
Bachmann D; Aliperta R; Bergmann R; Feldmann A; Koristka S; Arndt C; Loff S; Welzel P; Albert S; Kegler A; Ehninger A; Cartellieri M; Ehninger G; Bornhäuser M; von Bonin M; Werner C; Pietzsch J; Steinbach J; Bachmann M
Oncotarget; 2018 Jan; 9(7):7487-7500. PubMed ID: 29484126
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
Pishali Bejestani E; Cartellieri M; Bergmann R; Ehninger A; Loff S; Kramer M; Spehr J; Dietrich A; Feldmann A; Albert S; Wermke M; Baumann M; Krause M; Bornhäuser M; Ehninger G; Bachmann M; von Bonin M
Oncoimmunology; 2017; 6(10):e1342909. PubMed ID: 29123951
[TBL] [Abstract][Full Text] [Related]
19. Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á
Front Immunol; 2024; 15():1365172. PubMed ID: 38562932
[TBL] [Abstract][Full Text] [Related]
20. Impact of scFv on functionality and safety of third generation CD123 CAR T cells.
Fredon M; Poussard M; Biichlé S; Bonnefoy F; Mantion CF; Seffar E; Renosi F; Bôle-Richard E; Boidot R; Chevrier S; Anna F; Loustau M; Caumartin J; Gonçalves-Venturelli M; Robinet E; Saas P; Deconinck E; Daguindau E; Roussel X; Godet Y; Adotévi O; Angelot-Delettre F; Galaine J; Garnache-Ottou F
Cancer Immunol Res; 2024 May; ():. PubMed ID: 38819256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
